
Bio-Rad Laboratories is talks to merge with Qiagen in a deal that may be valued at more than $10 billion, The Wall Street Journal reported on Monday, citing people familiar with the matter.
While talks have been ongoing for some time, an agreement isn’t likely for a few weeks and the deal still may fall through, according to the report.
Spokespersons at both companies weren’t immediately available to comment when contacted by MedTech Dive.
Hercules, Calif.-based Bio-Rad makes various products for the life science research and clinical diagnostic markets. It has a market capitalization of just under $12 billion. Qiagen is a Germany-based diagnostics company, with a market capitalization of about $10 billion.
Thermo Fisher attempted to buy Qiagen in 2020 in a deal that was initially valued at $11.5 billion. That transaction fell apart after failing to secure support from Qiagen’s shareholders. Thermo Fisher went on to acquire research contractor PPD last year for $17.4 billion.
The report of a Bio-Rad tie up with Qiagen comes amid a lull of medtech mergers and acquisitions following a spending spree last year. Notable acquisitions this year include Stryker’s $3 billion purchase of Vocera Communications, ResMed’s approximately $1 billion pickup of MediFox Dan and Becton Dickinson’s $1.53 billion purchase of Parata Systems.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas